# EDGAR Filing Document

**Accession Number:** 0001403568
**File Stem:** 0001104659-25-099926
**Filing Date:** 2025-10
**Character Count:** 15749
**Document Hash:** 902aa806c4380a3adbb21b31d7717973
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-099926.hdr.sgml**: 20251016

**ACCESSION NUMBER**: 0001104659-25-099926

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251010

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251016

**DATE AS OF CHANGE**: 20251016

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ulta Beauty, Inc.
- **CENTRAL INDEX KEY:** 0001403568
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-RETAIL STORES, NEC [5990]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 384022268
- **FISCAL YEAR END:** 0201

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33764
- **FILM NUMBER:** 251396561

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 REMINGTON BLVD
- **STREET 2:** SUITE 120
- **CITY:** BOLINGBROOK
- **STATE:** IL
- **ZIP:** 60440
- **BUSINESS PHONE:** 630-410-4800

**MAIL ADDRESS:**
- **STREET 1:** 1000 REMINGTON BLVD
- **STREET 2:** SUITE 120
- **CITY:** BOLINGBROOK
- **STATE:** IL
- **ZIP:** 60440

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ulta Salon, Cosmetics & Fragrance, Inc.
- **DATE OF NAME CHANGE:** 20070618

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 10, 2025**

**ULTA BEAUTY, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**001-33764** | &nbsp;&nbsp;**38-4022268** |
| **(State or Other Jurisdiction<br> of Incorporation)** | **(Commission<br> File Number)** | **(IRS Employer<br> Identification No.)** |

---

**1000 Remington Blvd., Suite 120, Bolingbrook, Illinois 60440**

**(Address of Principal Executive Offices and zip code)**

**(630) 410-4800** 

**(Registrant's telephone number, including area code)**

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 C.F.R. §230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 C.F.R. §240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 C.F.R. §240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 C.F.R. §240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | ULTA | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp; ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp; ☐

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On October 10, 2025, the Board of Directors of Ulta Beauty, Inc. (the "Company" or "Ulta Beauty") appointed Christopher DelOrefice as the Company's Chief Financial Officer, as well as the Company's principal financial officer and principal accounting officer, effective December 5, 2025.

Mr. DelOrefice, 54, has served as Executive Vice President and Chief Financial Officer of Becton Dickinson & Company, a global medical technology company, since September 2021. Prior to Becton Dickinson & Company, Mr. DelOrefice spent over 20 years with Johnson & Johnson, a multinational pharmaceutical, biotechnology, and medical technologies company, and held financial leadership roles of increasing responsibility including as Vice President, Investor Relations from August 2018 to September 2021 and, prior to that, as Vice President, Finance and CFO, North America Hospital Medical Devices; and as Vice President, Finance and CFO, North America Consumer. Mr. DelOrefice serves on the Board of Directors for ResMed Inc. and serves as the Chair of ResMed's audit committee.

In connection with his appointment at Ulta Beauty, Mr. DelOrefice will receive an annual base salary of $980,000. Beginning in fiscal year 2026, Mr. DelOrefice will be eligible to receive an annual cash incentive with a target of 125% of base salary and a maximum of 200% of the target amount. Also beginning in fiscal year 2026, Mr. DelOrefice will be eligible to participate in the Company's long-term incentive program with a 2026 target grant value of 450% of base salary. These awards are expected to be granted in March 2026, in accordance with the Company's normal cadence and procedure for grants to executive officers, with half in the form of restricted stock units which vest on March 15, 2029, and half in stock options which vest in equal installments over four years beginning on March 15, 2027.

To compensate Mr. DelOrefice for certain equity awards that he will forfeit upon leaving his current employer and in consideration of the vesting schedules of those various awards, he will receive a sign-on cash payment of $1,000,000 (which is subject to repayment in the event of a voluntary termination or a termination for cause during his first year at Ulta Beauty), a grant of restricted stock units with a value of $1,100,000 which vest on the first anniversary of the grant date, and a grant of restricted stock units with a value of $2,200,000 which vest on the second anniversary of the grant date. These awards are expected to be granted in December 2025, subject to Mr. DelOrefice being employed on the grant date. All equity awards are subject to the provisions in the form award agreements applicable to senior officers of Ulta Beauty and the execution and continued compliance with a Confidential Information and Protective Covenant Agreement, which includes covenants with respect to non-competition and non-solicitation for a period of twelve months following termination of employment.

In addition, the Company will reimburse Mr. DelOrefice for travel and other expenses related to his relocation to the greater Chicago area for a period of twelve months following his start date, and for up to $20,000 of reasonable attorneys' fees incurred in connection with his offer of employment. If Mr. DelOrefice is involuntarily separated from the Company for reasons other than cause, he will be eligible to receive severance benefits commensurate with the benefits offered to executives at his job level in the Company under any policy then in effect, provided that he executes an effective release of claims at the time of termination.

There are no arrangements or understandings between Mr. DelOrefice and any other person pursuant to which he was appointed. Mr. DelOrefice does not have any family relationship with any director or other executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer, and there are no transactions in which Mr. DelOrefice has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Effective as of Mr. DelOrefice's appointment as Chief Financial Officer, principal financial officer and principal accounting officer, Christopher Lialios will no longer serve as the Company's Interim Chief Financial Officer, principal financial officer and principal accounting officer and will return to his former role of Senior Vice President, Controller.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On October 16, 2025, the Company issued a press release announcing the appointment of Mr. DelOrefice as Chief Financial Officer of the Company, effective December 5, 2025. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits. The exhibit listed in the Exhibit Index below is being filed herewith.

---

| | |
|:---|:---|
| *Exhibit <br> No.* | *Description* |
| [99.1](tm2528762d2_ex99-1.htm) | [Press release issued by Ulta Beauty, Inc. on October 16, 2025, announcing the Chief Financial Officer appointment.](tm2528762d2_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | ULTA BEAUTY, INC. | ULTA BEAUTY, INC. |
| Date: October 16, 2025 | By: | /s/ Rene G. Cásares |
|  |  | Rene G. Cásares |
|  |  | Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2528762d2_ex99-1img01.jpg)

**ULTA BEAUTY NAMES CHRISTOPHER DELOREFICE AS** 

**CHIEF FINANCIAL OFFICER**

BOLINGBROOK, Ill. October 16, 2025 – Ulta Beauty, Inc. (NASDAQ: ULTA), today announced that Christopher DelOrefice has been named as Ulta Beauty's next Chief Financial Officer. Mr. DelOrefice will begin his new role on December 5, 2025, and Chris Lialios will continue to serve as Interim Chief Financial Officer until such time.

Mr. DelOrefice is an experienced business leader who has led global, cross-functional teams at companies that have delivered superior financial performance. He joins Ulta Beauty from Becton Dickinson & Company, where he has served as Executive Vice President and Chief Financial Officer since September 2021. Prior to Becton Dickinson, Mr. DelOrefice spent more than 20 years with Johnson & Johnson, a multinational pharmaceutical, biotechnology, and medical technologies company, and held financial leadership roles of increasing responsibility including as Vice President, Investor Relations, Vice President Finance and CFO, North America Hospital Medical Devices, and Vice President Finance and CFO, North America Consumer. Earlier in his career, he held leadership positions in accounting, financial reporting, global audit, and supply chain finance at Astra Zeneca Pharmaceuticals, AET Films, Inc. and Ametek, Inc. Mr. DelOrefice is a Certified Public Accountant (inactive) and holds both a B.S. in Accounting and an M.B.A. from Villanova University. Mr. DelOrefice serves on the Board of Directors for ResMed and serves as the Chair of ResMed's audit committee.

"We are thrilled to welcome Chris to the Ulta Beauty family. Chris brings deep financial expertise and a proven track record of delivering leading financial performance and building high performing, engaged teams across global organizations," said Kecia Steelman, president and chief executive officer. "With demonstrated experience leading core finance functions, global operations, strategy, corporate development, and enterprise transformation for public companies, Chris will be a great partner to our team as we continue to execute our Ulta Beauty Unleashed strategy and deliver long-term value for all our stakeholders."

"Ulta Beauty is a formidable market leader in the beauty category, and I am excited to join this world-class organization," said Christopher DelOrefice. "I believe in the growth opportunity ahead for Ulta Beauty, and I look forward to working with Kecia and the team to drive long-term, sustainable profitable growth and shareholder value."

Steelman continued, "On behalf of the Ulta Beauty team and our Board of Directors, I want to thank Chris Lialios, who will transition back to his role as Senior Vice President – Controller, for serving as our Interim CFO throughout our search process. Chris's deep knowledge of Ulta Beauty, financial expertise and leadership enabled our teams to stay focused on delivering against our financial goals."

**About Ulta Beauty**

Ulta Beauty (NASDAQ: ULTA) is the largest specialty beauty retailer in the U.S. and a leading destination for cosmetics, fragrance, skin care, hair care, wellness and salon services. Since opening its first store in 1990, Ulta Beauty has grown to approximately 1,500 stores across the U.S. and redefined beauty retail by bringing together All Things Beauty. All in One Place®. With an expansive product assortment, professional salon services and its beloved Ulta Beauty Rewards loyalty program, the company delivers seamless, personalized experiences across stores, Ulta.com and the Ulta Beauty App – where the possibilities are truly beautiful. Ulta Beauty is also expanding its presence internationally through a joint venture in Mexico, a franchise in the Middle East, and its subsidiary, Space NK, a luxury beauty retailer operating in the U.K. and Ireland. For more information, visit <u>www.ulta.com</u>.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on Ulta Beauty's current expectations and are not guarantees of future performance. You can identify these forward-looking statements by the use of words such as "continues," "may," "will," "should," "could," "strategies," "plans" or the negative version of these words or other comparable words. The forward-looking statements include, among other things, statements regarding Ulta Beauty's expectations regarding its future performance and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory and other factors, including ongoing inflation and continued increases in interest rates, many of which are beyond Ulta Beauty's control. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ulta Beauty's filings with the Securities & Exchange Commission (the "SEC"), including Ulta Beauty's most recently filed Annual Report on Form 10-K, under the caption "Risk Factors," as may be updated from time to time in our periodic filings with the SEC. Any forward-looking statement in this press release speaks only as of the date of this release. Ulta Beauty undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

**Investor Contact:**<br> Kiley Rawlins, CFA

Vice President, Investor Relations

krawlins@ulta.com

**Media Contact:**

Crystal Carroll

Senior Director, Public Relations

ccarroll@ulta.com

# # #